We’re developing a cheap, fast and accurate point-of-care test for babies born to HIV-infected mothers. Help us take it forward into clinical trials.
Burnet Institute studies ranging from innovative antiviral strategies, to the development of new diagnostics, and research focused on vaccine development have attracted valuable funding from the Australian Centre for HIV and Hepatitis Virology Research (ACH2).
“A fabulous outcome” was how Burnet Head of Life Sciences, Professor Gilda Tachedjian described the grants awarded to Dr Rob Center, Dr Raffi Gugasyan, Dr Jess Howell, Dr Clovis Palmer, Dr Andy Poumbourios and Dr Jack Richards, at a success rate of 70 percent.
“The majority of the grants were from investigators in the Life Sciences discipline, so as Head of Life Sciences, I am especially thrilled,” Professor Tachedjian said.
“It shows the excellence of our work and the translational nature of our work in taking fundamental research and going that next step to develop some sort of diagnostic or anti-viral microbicide.”
Professor Tachedjian also received an ACH2 grant to extend her studies into whether lactic acid can alter the vaginal microbiome in women who have a disrupted microbiome, which is associated with an increased risk of HIV and other STIs.
“It provides us with funding to be able to do critical pre-clinical evaluation of our bespoke gels so that we can put together our ethics application to be able to do in vivo studies,” she said.
“We’re thrilled to have support from ACH2 to be able to do this important work.”